The Lean Stack: Peptides for Body Composition Without GLP-1s

1. Who the Lean Stack is for

GLP-1 agonists are the most effective weight loss drugs ever brought to market, but they are not the right fit for everyone. The Lean Stack exists for three groups of patients in particular:

• GLP-1 intolerant. Some people cannot get past the nausea, vomiting, constipation, or reflux that GLP-1 agonists commonly produce. For these patients the issue is not motivation, it is that the gut side effects make the drug unlivable.
• Plateaued. Patients who lost weight on a GLP-1 and then stalled sometimes want a mechanistically different push rather than escalating a dose that is already causing side effects.
• Contraindicated. A personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, or severe gastroparesis can put GLP-1 agonists off the table entirely. These patients still want body composition help through a different door.

The Lean Stack is not a stronger alternative to a GLP-1. It is a different-side-effect alternative. The honest framing matters: you are trading the GI profile of a GLP-1 for the cardiovascular and sleep profile of a stimulant, plus a lean-mass-preservation layer that a GLP-1 does not provide.

2. The three components

The Lean Stack is built from three agents, each attacking body composition through a separate pathway. The point of the design is that no single mechanism has to carry the whole load, which is what keeps any one side-effect profile from dominating.

One thing to flag before the detail sections: the brief-named trio is the conceptual Lean Stack. RxPepsDirect also lists a pre-blended four-peptide vial called the Lean Stack (AOD-9604/MOTs-C/Tesamorelin/Ipamorelin) that swaps tesofensine out and adds MOTs-C and tesamorelin into a single injection. The principle is identical: stack complementary fat-loss mechanisms rather than lean on one. Which version a provider chooses depends on whether you want an oral appetite agent in the mix or an all-injectable vial.

3. AOD-9604: the lipolysis fragment

AOD-9604 is a modified fragment (residues 176-191) of the C-terminus of human growth hormone. It was engineered to keep the fat-mobilizing tail of the GH molecule while dropping the parts that raise blood sugar or drive systemic growth. In theory that gives you lipolysis without the IGF-1 elevation and glucose effects of full growth hormone.

What the evidence actually shows. Based on articles retrieved from PubMed, the strongest AOD-9604 data is preclinical. In obese mice, chronic AOD-9604 administration reduced body weight and body fat and increased beta-3 adrenergic receptor expression in fat cells, the major lipolytic receptor (Heffernan et al., Endocrinology 2001, DOI 10.1210/endo.142.12.8522). That is a clean mechanistic story in rodents.

The honest caveat. Human obesity trials did not reproduce a clear standalone weight loss benefit, which is why a search of the human clinical-trial literature returns no positive obesity RCT for AOD-9604. The label of "fat-burning peptide" oversells it. Inside the Lean Stack, AOD-9604 is a supporting lipolysis agent, not the engine. It earns its place because it adds a fat-cell mechanism without contributing to the stimulant load, not because it independently melts fat.

Catalog detail: AOD-9604 is listed at $80 per 6 mg vial, dosed at 20 units (0.24 mg) subcutaneously Monday through Friday, typically run 8 to 12 weeks on with a 2 to 4 week break. It is generally well tolerated and avoided in pregnancy.

4. Tesofensine: appetite and thermogenesis

Tesofensine is the best-evidenced component of the Lean Stack and the one doing the heaviest lifting on actual weight loss. It is a triple monoamine reuptake inhibitor: it blocks the reuptake of norepinephrine, dopamine, and serotonin, which suppresses appetite and modestly raises resting metabolic rate.

The human trial. According to PubMed, the Phase II TIPO-1 study (Astrup et al., Lancet 2008) randomized 203 obese patients to tesofensine 0.25 mg, 0.5 mg, 1.0 mg, or placebo for 24 weeks alongside an energy-restricted diet. The 0.5 mg dose produced a mean 9.2 percent weight loss versus 2.0 percent on diet plus placebo (DOI 10.1016/S0140-6736(08)61525-1). The authors noted this was roughly double the effect of the weight-loss drugs approved at the time. The most common adverse events were dry mouth, nausea, constipation, hard stools, diarrhea, and insomnia, and the 0.5 mg dose raised heart rate by about 7 beats per minute.

Read that honestly. 9 percent at 24 weeks is meaningful, but it is a Phase II result that the authors themselves said needed Phase III confirmation, and it is well short of what GLP-1 agonists achieve. Tesofensine is a real appetite tool with a real stimulant cost, not a GLP-1 killer.

Catalog detail: Tesofensine is an oral capsule, 500 mcg once daily in the morning, priced at $2.25 per capsule across a 28-count fill. It is explicitly not combined with semaglutide or tirzepatide, and it is contraindicated in uncontrolled hypertension, cardiovascular disease, stroke history, and anxiety disorders, and must not be taken with MAOIs.

→ Full dosing and titration: Tesofensine protocol guide

5. CJC-1295/Ipamorelin: lean mass preservation

The risk with any aggressive fat-loss protocol is that you lose muscle along with the fat. GLP-1 monotherapy is notorious for this: a meaningful fraction of GLP-1 weight loss can be lean mass. The Lean Stack addresses that directly by including a growth hormone secretagogue.

CJC-1295/Ipamorelin pairs two complementary mechanisms. CJC-1295 is a GHRH analog that extends the window of GHRH-receptor stimulation, amplifying each natural GH pulse. Ipamorelin is a selective ghrelin receptor agonist that triggers additional GH release without the cortisol or prolactin spikes of older GHRP peptides. Together they produce a clean, pulsatile GH release that supports lean tissue, recovery, and sleep during a caloric deficit.

Why it belongs here. Its job in the Lean Stack is not to add fat loss, it is to defend lean mass and recovery so that the weight you lose is preferentially fat. Better sleep and recovery also make it easier to maintain the resistance training that actually protects muscle.

Catalog detail: CJC-1295/Ipamorelin is listed at $100 per 10 mg + 10 mg vial, dosed at 20 units (0.4 mg/0.4 mg) subcutaneously five evenings per week, timed to the natural nocturnal GH surge. It is contraindicated in active cancer, pituitary tumors, diabetic retinopathy, and pregnancy.

→ Full dosing, syringe math, and the 90-day rule: CJC-1295/Ipamorelin protocol guide

6. Why this stack avoids GLP-1 GI side effects

GLP-1 agonists produce most of their effect, and most of their side effects, through the same place: the gut-brain appetite axis. Slowed gastric emptying is part of how they suppress appetite, and it is also why nausea, fullness, constipation, and reflux are so common. You cannot easily separate the benefit from the GI burden because they share a mechanism.

The Lean Stack distributes its work so that no single pathway has to be pushed hard enough to dominate:

• Tesofensine works centrally on monoamines, not by slowing the stomach, so its appetite effect does not come bundled with gastroparesis-style symptoms. Its side effects show up as dry mouth, insomnia, and cardiovascular changes instead.
• AOD-9604 acts at the fat cell, with essentially no central appetite or GI footprint.
• CJC-1295/Ipamorelin works at the pituitary, again outside the GI tract.

The result is a protocol with little of the nausea-and-constipation signature that drives many people off GLP-1s. The honest tradeoff: you move the side-effect burden from the gut to the cardiovascular system and sleep. That is the whole reason blood pressure, resting heart rate, and sleep are the monitoring priorities in section 8, not GI tolerance.

7. Sample 12-week protocol

This is an illustrative protocol, not a prescription. Exact agents, doses, and timing are a licensed provider's decision based on your intake, vitals, and goals. It is shown so you understand the shape of a Lean Stack cycle.

Weeks 1 to 4: ramp

• Tesofensine: 500 mcg orally each morning
• AOD-9604: 0.24 mg (20 units) subcutaneous Monday through Friday
• CJC-1295/Ipamorelin: 0.4 mg/0.4 mg (20 units) subcutaneous five evenings per week

Goal: establish tolerance to the stimulant load. The provider checks in on heart rate, blood pressure, and sleep before continuing.

Weeks 5 to 8: assess

Recheck resting heart rate, blood pressure, and sleep quality. If the stimulant load is well tolerated, continue all three agents. If heart rate or blood pressure is climbing or sleep is disrupted, the provider reduces or pauses tesofensine first, since it carries the cardiovascular signal.

Weeks 9 to 12: consolidate

Hold the protocol with continued resistance training and adequate protein, which is what actually protects the lean mass the CJC-1295/Ipamorelin layer is defending. AOD-9604 then cycles off for 2 to 4 weeks after week 12. Body composition and any relevant labs are reassessed with the provider before deciding whether to repeat, modify, or stop.

8. Side effects and monitoring

The Lean Stack's monitoring burden is real, and it is different from a GLP-1's. The priority is the stimulant component, not the gut.

• Cardiovascular. Tesofensine raised heart rate by roughly 7 beats per minute at 0.5 mg in the TIPO-1 trial. Blood pressure and resting heart rate should be checked at baseline and through the cycle. Palpitations, chest discomfort, or a rising heart rate are reasons to stop and contact the provider.
• Sleep and mood. Insomnia and anxiety can show up from the monoamine effect. People with an anxiety disorder are not candidates for tesofensine.
• Anticholinergic-type effects. Dry mouth and constipation were common in the trial, so the stack is not entirely GI-free, just free of the gastroparesis-style profile of GLP-1s.
• GH-axis effects. CJC-1295/Ipamorelin can cause water retention, tingling, or transient glucose changes, and is contraindicated in active cancer, pituitary tumors, and diabetic retinopathy.

Across the stack, the monitoring shorthand is: watch blood pressure, heart rate, and sleep. Those three signals are where this protocol gets you into trouble if it is going to, which is exactly why provider supervision is non-negotiable.

9. Comparison: Lean Stack vs GLP-1 stack

The honest side-by-side. This is meant to set expectations, not to argue that one is universally better.

The bottom line: a GLP-1 stack wins on raw weight-loss magnitude. The Lean Stack wins for people who cannot take a GLP-1, who want lean mass defended, or who would rather manage a cardiovascular profile than a GI one. For a deeper look at combining fat loss with muscle retention, see the peptide stack for fat loss and muscle.

10. Contraindications and patient selection

The Lean Stack is the wrong choice for a meaningful number of people, and the stimulant component is the reason. A provider will rule it out if any of the following apply:

• Uncontrolled hypertension or known cardiovascular disease
• History of stroke or significant arrhythmia
• An anxiety disorder, or current MAOI use
• Active cancer, pituitary tumor history, or diabetic retinopathy (the GH-secretagogue contraindications)
• Pregnancy or breastfeeding

Who it fits best. An otherwise cardiovascularly healthy adult who cannot tolerate or cannot take a GLP-1, who is willing to train and eat in a deficit, and who wants to protect lean mass while losing fat. The Lean Stack rewards people who treat it as one input alongside training and nutrition, and disappoints anyone expecting a passive fat-loss shortcut. Non-responders exist for every component here, which is why the provider reassesses at the points built into the protocol.

11. How to get a Lean Stack prescription

The Lean Stack components are available through a licensed telehealth provider and a 503A compounding pharmacy. The process:

1. Online intake. Complete a structured health history including cardiovascular history, current medications, cancer history, and goals. No in-person clinic visit is required.
2. Provider review. A licensed provider reviews your intake and screens specifically for the stimulant contraindications before prescribing tesofensine. Baseline blood pressure and heart rate are part of the picture.
3. Prescription and fill. RxPepsDirect writes the prescription only. Optimal Balance Pharmacy, a 503A licensed pharmacy, fills it, ships it, and collects the medication payment. The injectable components ship pre-reconstituted, FedEx overnight, in a reusable cooled travel case, so there is no mixing on your end.
4. Monitoring. Follow-up check-ins track blood pressure, heart rate, sleep, and body composition so the provider can continue, dose-adjust, or stop the protocol.

Telehealth access is currently available in 28 U.S. States. Eligibility is confirmed during intake.